SCHEMBL6546158

SCHEMBL6546158

C=CCOP(=O)(O)c1ccccc1Oc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
GAA P10253 2/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
RAB9A P51151 2/20 0.38
GLA P06280 1/20 0.38
LIG1 P18858 1/20 0.38
PTK2B Q14289 2/20 0.37
ALPG P10696 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
CTNNB1 P35222 1/20 0.36
PKM P14618 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
POLB P06746 3/20 0.36
NPC1 O15118 2/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diphenylether SCHEMBL28670517 0.79 SMN1; SMN2 (0.47) ALDH1A1GAAKMT2AHTTSMN1; SMN2
Diphenylether SCHEMBL23151830 0.77 SMN1; SMN2 (0.46) ALDH1A1GAAKMT2AHTTSMN1; SMN2
SCHEMBL8651877 0.77 CYP3A4 (0.39) ALDH1A1KMT2ASMN1; SMN2RAB9ALIG1
SCHEMBL6545928 0.76 GAA (0.46) ALDH1A1GAALMNAKMT2AHTT
SCHEMBL3468614 0.75 TSHR (0.50) ALDH1A1GAAKMT2ASMN1; SMN2LIG1
SCHEMBL28332945 0.75 ALDH1A1 (0.41) ALDH1A1KMT2ASMN1; SMN2LIG1PKM
SCHEMBL6546173 0.75 GABRA1 (0.38) ALDH1A1KMT2AHTTSMN1; SMN2LIG1
SCHEMBL11050910 0.74 CTNNB1 (0.47) ALDH1A1GAALMNAKMT2AHTT
SCHEMBL10972815 0.74 PTK2B (0.56) ALDH1A1GAALMNAKMT2AHTT
SCHEMBL11884152 0.74 GAA (0.46) ALDH1A1GAAHTTSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379533-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS Leo Pharma A/S (DK) 2004-01-14 EP disclosed
US-6605742-B2 Rheumatic diseases; antiarthritic agents; antitumor agents LEO PHARMA A/S (DK) 2003-08-12 US disclosed
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons LEO PHARMA A/S (DK) 2002-11-28 US disclosed
WO-2002083696-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS LEO PHARMA A/S (DK) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons CMA1, MMP9, CPA1 ALDH1A1 1152/4885GAA 701/4885LMNA 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.